Morgan Stanley assumed coverage of Zenas BioPharma (ZBIO) with an Overweight rating with a price target of $31, down from $35. Upcoming readouts in 4Q25 the first half of 2026 could demonstrate the potential of inhibiting B cells in autoimmune conditions while building out the pipeline-in-a-product potential of obexelima, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
- Zenas BioPharma Announces Board Changes at Annual Meeting
- Zenas BioPharma to Present at Jefferies Conference
- Zenas BioPharma Reports Q1 2025 Financial Results
- Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating